Authors: Molinier-Frenkel, V Le Boulaire, C Le Gal, FA Gahery-Segard, H Tursz, T Guillet, JG Farace, F

Citation: V. Molinier-frenkel et al., Longitudinal follow-up of cellular and humoral immunity induced by recombinant adenovirus-mediated gene therapy in cancer patients, HUM GENE TH, 11(13), 2000, pp. 1911-1920

Authors: Guichard, G Zerbib, A Le Gal, FA Hoebeke, J Connan, F Choppin, J Briand, JP Guillet, JG

Citation: G. Guichard et al., Melanoma peptide MART-1(27-35) analogues with enhanced binding capacity tothe human class I histocompatibility molecule HLA-A2 by introduction of a beta-amino acid residue: Implications for recognition by tumor-infiltratinglymphocytes, J MED CHEM, 43(20), 2000, pp. 3803-3808

Authors: Le Gal, FA Riteau, B Sedlik, C Khalil-Daher, I Menier, C Dausset, J Guillet, JG Carosella, ED Rouas-Freiss, N

Citation: Fa. Le Gal et al., HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes, INT IMMUNOL, 11(8), 1999, pp. 1351-1356

Authors: Paul, P Cabestre, FA Le Gal, FA Khalil-Daher, I Le Danff, C Schmid, M Mercier, S Avril, MF Dausset, J Guillet, JG Carosella, ED

Citation: P. Paul et al., Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies, CANCER RES, 59(8), 1999, pp. 1954-1960